AKT1 and acute myeloid leukemia: Indeed, recent work has shown that CK2 inhibition dampens down the PI3K/AKT pathway with a reduction of the activity of downstream effectors such as Bcl-xl and NF-κB and cooperates with PI3K inhibitors in inducing cell death of CD34+ CD38- AML leukemia stem cells [50].